Alentis Therapeutics’ Post

Since the inception of Alentis in 2019, we have grown to over fifty employees, started four clinical trials, and created the first two ADCs targeting Claudin-1. In this latest video our CEO Roberto Iacone and Founder Prof Thomas Baumert reveal the incredible journey from the humble beginnings till now and our bold aspirations for the future. We remain the leading biotech company developing anti-Claudin-1 therapies and are rapidly advancing our clinical pipeline to address the unmet medical needs of patients suffering from Claudin-1 positive solid tumors and organ fibrosis. Learn more at www.alentis.ch #AlentisTherapeutics #Biotech #Claudin #CLDN1

We are proud to announce that our Chief Medical Officer, Luigi Manenti, will be presenting at Venrock’s 8th Annual European Investor Tour from July 9-11 in London, UK. He will be joined by our founder, Thomas Baumert, who discovered the anti-Claudin-1 antibody, the foundation of our pipeline programs targeting cancer and fibrosis. #AlentisTherapeutics #Biotech #London

Team Alentis is participating in the Leerink Partners Biopharma Private Company Connect event being held virtually June 25 and 26. They´ll be highlighting our pipeline of first-in-class Claudin-1 targeting mAbs and ADCs in oncology and organ fibrosis. #AlentisTherapeutics #Biotech #Biopharma

The FDA has granted lixudebart (ALE.F02) Orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This first-in-class monoclonal antibody is in development for liver, lung and kidney fibrosis and this designation underscores the urgent medical need for an effective IPF treatment. Read the full press release: https://lnkd.in/eNXS-TZv   Prof. Steven Nathan said, “IPF patients do not have transformative treatment options and often experience tolerability challenges with the current standard of care drugs. Alentis is doing important work on developing lixudebart as a treatment targeting the root causes of disease. This molecule has shown a very favorable safety profile in Phase 1, and I would be thrilled to see lixudebart tested in IPF patients in the future.”   #AlentisTherapeutics #Fibrosis #FDA #RareDisease #IPF

Swiss Biotech is booming! 2023 was an exceptional year, not just for Alentis but for the entire Swiss Biotech industry. Could 2024 be even better?

It is International Vasculitis Day! Today we shine a light on #vasculitis and in particular ANCA-associated vasculitis (AAV). Vasculitis is used to describe a family of nearly 20 rare autoimmune diseases characterized by inflammation of the blood vessels which can damage vital organs. In the majority of AAV cases the kidneys are affected, and this often leads to significant or total loss of kidney function. At Alentis we are determined to develop lixudebart (ALE.F02) an investigational treatment to recover kidney function in AAV patients. Find out more on https://lnkd.in/gZPXSBa #VasculitisAwareness #vam2024 #ANCAVasculitis 

Today we announced two presentations at the European Renal Association (ERA) and American Thoracic Society (ATS) conferences this May. The outstanding work performed by the research groups at @KULeuven and @Inserm show that #CLDN1 plays a key role in the early pathogenesis of #fibrosis. It further validates CLDN1 as a therapeutic target across fibrotic indications, in this case #IPF and crescentic #glomerulonephritis in ANCA-associated vasculitis. Read the full release: https://lnkd.in/ehzix_xk #AlentisTherapeutics #ERA24 #ATS2024 #Nephrology #Claudin

Excited to attend Bio€quity Europe! Our CEO, Roberto Iacone will give a company presentation on May 13 at 10:30 CET. Do reach out in case you want to meet up. #Bio€quity #Biotech #SeeYouThere